B-intervention	0	10	Systematic
O	11	17	versus
B-control	18	26	sentinel
I-control	26	27	-
I-control	27	32	lymph
I-control	32	33	-
I-control	33	37	node
I-control	37	38	-
I-control	38	44	driven
I-control	45	53	axillary
I-control	53	54	-
I-control	54	59	lymph
I-control	59	60	-
I-control	60	64	node
I-control	65	75	dissection
O	76	78	in
O	79	89	clinically
O	90	94	node
O	94	95	-
O	95	103	negative
O	104	112	patients
O	113	117	with
O	118	126	operable
O	127	133	breast
O	134	140	cancer
O	140	141	.

O	142	149	Results
O	150	152	of
O	153	156	the
O	157	159	GF
O	159	160	-
O	160	164	GS01
O	165	175	randomized
O	176	181	trial
O	181	182	.

O	183	191	Sentinel
O	191	192	-
O	192	197	lymph
O	197	198	-
O	198	202	node
O	203	204	(
O	204	207	SLN
O	207	208	)
O	209	218	resection
O	219	224	seems
O	225	227	to
O	228	236	minimize
O	237	247	systematic
O	248	256	axillary
O	256	257	-
O	257	262	lymph
O	262	263	-
O	263	267	node
O	268	278	dissection
O	279	280	(
O	280	285	sALND
O	285	286	)
O	287	291	side
O	292	299	effects
O	300	302	in
O	303	311	operated
O	312	318	breast
O	319	325	cancer
O	326	334	patients
O	334	335	.

O	336	338	We
O	339	347	explored
O	348	355	whether
O	356	359	SLN
O	360	369	resection
O	370	378	achieves
O	379	386	similar
O	387	398	therapeutic
O	399	407	outcomes
O	408	410	as
O	411	416	sALND
O	417	420	but
O	421	425	with
O	426	431	fewer
O	432	436	side
O	437	444	effects
O	444	445	.

O	446	447	A
O	448	458	randomized
O	458	459	,
O	460	470	controlled
O	470	471	,
O	472	476	open
O	476	477	-
O	477	482	label
O	483	488	trial
O	489	493	with
O	494	502	parallel
O	502	503	-
O	503	508	group
O	509	515	design
O	516	524	compared
O	525	530	sALND
O	531	541	restricted
O	542	544	to
O	545	550	cases
O	551	555	with
O	556	564	positive
O	565	568	SLN
O	569	575	biopsy
O	576	577	(
O	577	581	test
O	582	585	arm
O	585	586	,
O	587	588	n
O	589	590	=
B-intervention-participants	591	594	774
O	594	595	)
O	596	602	versus
O	603	606	SLN
O	607	613	biopsy
O	614	622	followed
O	623	625	by
O	626	631	sALND
O	632	633	(
O	633	640	control
O	641	644	arm
O	644	645	,
O	646	647	n
O	648	649	=
B-control-participants	650	653	770
O	653	654	)
O	654	655	.

O	656	659	The
B-outcome	660	664	five
I-outcome	664	665	-
I-outcome	665	669	year
I-outcome	670	677	overall
I-outcome	678	687	survivals
O	688	690	in
O	691	698	control
O	699	702	and
O	703	707	test
O	708	712	arms
O	713	717	were
B-iv-bin-percent	718	720	96
I-iv-bin-percent	720	721	.
I-iv-bin-percent	721	723	42
O	724	727	and
B-cv-bin-percent	728	730	95
I-cv-bin-percent	730	731	.
I-cv-bin-percent	731	733	64
I-cv-bin-percent	733	734	%
O	735	736	(
O	736	737	P
O	738	739	=
O	740	741	0
O	741	742	.
O	742	746	2925
O	746	747	)
O	747	748	.

O	749	752	The
O	753	762	estimated
O	763	773	difference
O	774	777	was
O	778	784	nearly
O	785	789	zero
O	790	791	(
O	791	800	precisely
O	800	801	,
O	802	803	-
O	804	805	0
O	805	806	.
O	806	808	79
O	808	809	%
O	809	810	,
O	811	814	one
O	814	815	-
O	815	821	tailed
O	822	824	95
O	824	825	%
O	826	836	confidence
O	837	845	interval
O	846	847	(
O	847	849	CI
O	849	850	)
O	851	856	limit
O	857	858	-
O	859	860	2
O	860	861	.
O	861	863	44
O	863	864	%
O	864	865	)
O	865	866	.

O	867	869	In
O	870	871	a
O	872	884	multivariate
O	885	888	Cox
O	889	894	model
O	894	895	,
O	896	899	the
O	900	908	adjusted
O	909	915	hazard
O	916	921	ratio
O	922	924	in
O	925	928	the
O	929	933	test
O	934	937	arm
O	938	941	was
O	942	944	HR
O	945	946	0
O	946	947	.
O	947	949	81
O	950	951	(
O	951	956	upper
O	957	959	95
O	959	960	%
O	961	963	CI
O	964	969	limit
O	970	971	1
O	971	972	.
O	972	974	17
O	974	975	)
O	975	976	.

O	977	985	Advanced
O	986	989	age
O	990	991	(
O	991	993	HR
O	994	995	1
O	995	996	.
O	996	998	05
O	999	1002	per
O	1003	1013	additional
O	1014	1018	year
O	1018	1019	,
O	1020	1022	CI
O	1023	1024	[
O	1024	1025	1
O	1025	1026	.
O	1026	1028	03
O	1028	1029	-
O	1029	1030	1
O	1030	1031	.
O	1031	1033	08
O	1033	1034	]
O	1034	1035	)
O	1035	1036	,
O	1037	1045	negative
O	1046	1058	progesterone
O	1059	1067	receptor
O	1068	1069	(
O	1069	1071	HR
O	1072	1073	2
O	1073	1074	.
O	1074	1076	17
O	1077	1078	[
O	1078	1079	1
O	1079	1080	.
O	1080	1082	35
O	1082	1083	-
O	1083	1084	3
O	1084	1085	.
O	1085	1087	45
O	1087	1088	]
O	1088	1089	)
O	1089	1090	,
O	1091	1094	SLN
O	1095	1105	metastasis
O	1106	1107	(
O	1107	1109	HR
O	1110	1111	1
O	1111	1112	.
O	1112	1114	69
O	1115	1116	[
O	1116	1117	1
O	1117	1118	.
O	1118	1120	03
O	1120	1121	-
O	1121	1122	2
O	1122	1123	.
O	1123	1125	79
O	1125	1126	]
O	1126	1127	)
O	1127	1128	,
O	1129	1132	and
O	1133	1137	only
O	1138	1141	one
O	1142	1145	SLN
O	1146	1160	identification
O	1161	1170	technique
O	1171	1172	(
O	1172	1174	HR
O	1175	1176	4
O	1176	1177	.
O	1177	1179	14
O	1180	1181	[
O	1181	1182	1
O	1182	1183	.
O	1183	1185	21
O	1185	1186	-
O	1186	1188	14
O	1188	1189	.
O	1189	1191	18
O	1191	1192	]
O	1192	1193	)
O	1194	1198	were
O	1199	1209	associated
O	1210	1214	with
O	1215	1220	lower
O	1221	1229	survival
O	1229	1230	.

O	1231	1239	Patients
O	1240	1244	with
B-outcome	1245	1246	â‰¥
I-outcome	1247	1248	1
I-outcome	1249	1255	severe
I-outcome	1256	1260	side
I-outcome	1261	1267	effect
O	1268	1270	at
O	1271	1272	1
O	1273	1278	month
O	1279	1281	in
O	1282	1289	control
O	1290	1293	and
O	1294	1298	test
O	1299	1303	arms
O	1304	1308	were
B-cv-bin-abs	1309	1312	173
O	1312	1313	/
B-control-participants	1313	1316	703
O	1317	1318	=
B-cv-bin-percent	1319	1321	24
I-cv-bin-percent	1321	1322	.
I-cv-bin-percent	1322	1323	6
I-cv-bin-percent	1323	1324	%
O	1325	1326	[
O	1326	1328	21
O	1328	1329	.
O	1329	1330	5
O	1330	1331	-
O	1331	1333	28
O	1333	1334	.
O	1334	1335	0
O	1335	1336	%
O	1336	1337	]
O	1338	1341	and
B-iv-bin-abs	1342	1344	91
O	1344	1345	/
B-intervention-participants	1345	1348	693
O	1349	1350	=
B-iv-bin-percent	1351	1353	13
I-iv-bin-percent	1353	1354	.
I-iv-bin-percent	1354	1355	1
I-iv-bin-percent	1355	1356	%
O	1357	1358	[
O	1358	1360	10
O	1360	1361	.
O	1361	1362	7
O	1362	1363	-
O	1363	1365	15
O	1365	1366	.
O	1366	1367	9
O	1367	1368	%
O	1368	1369	]
O	1370	1371	(
O	1371	1372	P
O	1373	1374	<
O	1375	1376	0
O	1376	1377	.
O	1377	1380	001
O	1380	1381	)
O	1381	1382	.

O	1383	1386	The
B-outcome	1387	1396	estimated
I-outcome	1397	1408	sensitivity
I-outcome	1409	1411	of
I-outcome	1412	1415	SLN
I-outcome	1416	1422	biopsy
O	1423	1424	(
O	1424	1431	control
O	1432	1435	arm
O	1435	1436	)
O	1437	1440	was
B-cv-bin-abs	1441	1444	145
O	1444	1445	/
B-control-participants	1445	1448	178
O	1449	1450	=
B-cv-bin-percent	1451	1453	81
I-cv-bin-percent	1453	1454	.
I-cv-bin-percent	1454	1455	5
I-cv-bin-percent	1455	1456	%
O	1457	1458	[
O	1458	1460	74
O	1460	1461	.
O	1461	1462	8
O	1462	1463	-
O	1463	1465	86
O	1465	1466	.
O	1466	1467	7
O	1467	1468	%
O	1468	1469	]
O	1469	1470	.

O	1471	1482	Restricting
O	1483	1487	ALND
O	1488	1490	to
O	1491	1496	cases
O	1497	1501	with
O	1502	1510	positive
O	1511	1514	SLN
O	1515	1521	biopsy
O	1522	1526	does
O	1527	1530	not
O	1531	1537	affect
O	1538	1541	the
O	1542	1549	overall
O	1550	1558	survival
O	1559	1562	but
O	1563	1570	reduces
O	1571	1573	by
O	1574	1576	11
O	1576	1577	.
O	1577	1578	5
O	1578	1579	%
O	1580	1581	[
O	1581	1582	7
O	1582	1583	.
O	1583	1584	5
O	1584	1585	-
O	1585	1587	15
O	1587	1588	.
O	1588	1589	6
O	1589	1590	%
O	1590	1591	]
O	1592	1593	(
O	1593	1594	P
O	1595	1596	<
O	1597	1598	0
O	1598	1599	.
O	1599	1602	001
O	1602	1603	)
O	1604	1607	the
O	1608	1612	risk
O	1613	1615	of
O	1616	1622	severe
O	1623	1628	short
O	1628	1629	-
O	1629	1633	time
O	1634	1638	side
O	1639	1646	effects
O	1647	1649	of
O	1650	1655	sALND
O	1655	1656	.
